Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | HAT1 | O14929 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817519 | 0.88 | NAMPT (0.51) | CYP2C19CYP3A4NAMPTHASPINHTR6 | |
| SCHEMBL2628950 | 0.87 | CYP2D6 (0.48) | CYP2C19HASPINHAT1EP300MEN1 | |
| Potassium Ion SCHEMBL3887398 | 0.85 | NAMPT (0.47) | CYP2C19CYP3A4NAMPTHASPINHTR6 | |
| SCHEMBL3887392 | 0.85 | HTR6 (0.46) | CYP2C19CYP3A4NAMPTHASPINHTR6 | |
| SCHEMBL29688274 | 0.81 | NR4A2 (0.47) | CYP2C19CYP3A4NAMPTHASPINHTR6 | |
| SCHEMBL3236458 | 0.81 | NR4A2 (0.47) | CYP2C19CYP3A4NAMPTHASPINHTR6 | |
| SCHEMBL22049722 | 0.81 | ALDH1A1 (0.59) | CYP2C19CYP3A4NAMPTHASPINHTR6 | |
| SCHEMBL12481581 | 0.81 | HASPIN (0.64) | CYP2C19CYP3A4NAMPTHASPINHTR6 | |
| SCHEMBL30066929 | 0.80 | GPR84 (0.51) | CYP2C19CYP3A4NAMPTROCK1HAT1 | |
| SCHEMBL6778035 | 0.79 | KDM4E (0.55) | CYP2C19NAMPTHASPINHTR6ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2019-04-18 | — | — | US | disclosed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| WO-2005090367-A1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
| US-6900323-B2 | Antiviral azaindole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1257276-A4 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040023982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| US-6632819-B1 | HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-14 | — | — | US | disclosed |
| EP-1257276-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| US-20020061892-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| WO-2001062255-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | CYP2C19 3101/4885CYP3A4 491/4885NAMPT 892/4885 |
| US-20020061892-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | CYP2C19 3101/4885CYP3A4 491/4885NAMPT 892/4885 |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | CYP2C19 435/4885CYP3A4 1322/4885NAMPT 4270/4885 |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | CYP2C19 631/4885CYP3A4 1585/4885NAMPT 4070/4885 |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | CYP2C19 435/4885CYP3A4 1322/4885NAMPT 4270/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | CYP2C19 402/4885CYP3A4 1334/4885NAMPT 4288/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | CYP2C19 435/4885CYP3A4 1322/4885NAMPT 4270/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | CYP2C19 435/4885CYP3A4 1322/4885NAMPT 4270/4885 |
| US-20040023982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, EIF2AK2 | CYP2C19 3009/4885CYP3A4 589/4885NAMPT 1042/4885 |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | CYP2C19 435/4885CYP3A4 1322/4885NAMPT 4270/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | CYP2C19 3510/4885CYP3A4 3773/4885NAMPT 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.